Prasugrel and clopidogrel are thienopyridine derivatives with adenosine diphosphate (ADP)--antagonistic activity and are widely used in clinics for the prevention of ischemic events in patients with ST‐segment‐elevated and non‐ST‐segment‐elevated myocardial infarction (STEMI and NSTEMI, respectively) who are undergoing percutaneous coronary intervention (PCI).[1](#cpdd259-bib-0001){ref-type="ref"}, [2](#cpdd259-bib-0002){ref-type="ref"}, [3](#cpdd259-bib-0003){ref-type="ref"} Rapid, potent, and consistent inhibition of platelet aggregation is important in patients with acute STEMI undergoing PCI.[4](#cpdd259-bib-0004){ref-type="ref"}, [5](#cpdd259-bib-0005){ref-type="ref"} Compared with the effect of clopidogrel, prasugrel rapidly and more potently inhibits platelet aggregation.[6](#cpdd259-bib-0006){ref-type="ref"} In STEMI patients undergoing PCI, prasugrel has been shown to be more effective than clopidogrel in reducing the risk of cardiovascular mortality, myocardial infarction, and stroke, as well as stent thrombosis.[1](#cpdd259-bib-0001){ref-type="ref"}

Prasugrel and clopidogrel are inactive prodrugs that are converted to active metabolites that bind irreversibly to the platelet ADP receptor P2Y12. The conversion of clopidogrel to the active metabolite has been reported to be a 2‐step, CYP‐dependent process (mainly CYP2C19).[7](#cpdd259-bib-0007){ref-type="ref"}, [8](#cpdd259-bib-0008){ref-type="ref"} On the other hand, prasugrel is metabolized by esterases in the intestines and is subsequently metabolized by the CYP450 3A, 2B6, 2C9, and 2C19 isoforms.[9](#cpdd259-bib-0009){ref-type="ref"}, [10](#cpdd259-bib-0010){ref-type="ref"} In previous clinical studies, 20% to 30% of the patients treated with clopidogrel showed low or no inhibition of ADP‐induced platelet aggregation by CYP2C19 polymorphisms, as measured by ex vivo aggregometry.[11](#cpdd259-bib-0011){ref-type="ref"}, [12](#cpdd259-bib-0012){ref-type="ref"}

To our knowledge, the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel at a dose adjusted for Japanese patients have not been compared in a clinical study. Therefore, we investigated the clinically relevant pharmacological parameters of prasugrel at a loading dose of 20 mg in healthy Japanese subjects and compared them with those of clopidogrel at a loading dose of 300 mg. Furthermore, we studied the potential effect of CYP2C19 polymorphisms on these parameters.

Methods {#cpdd259-sec-0020}
=======

Subjects {#cpdd259-sec-0030}
--------

The present study was conducted in accordance with the Declaration of Helsinki and practice and ethical guidelines for clinical studies. The study protocol was approved by the Institutional Review Board for Human Studies of Hamamatsu University School of Medicine, Hamamatsu, Japan (approval number RG14‐024). Written informed consent was obtained from each subject before participation in the study. Forty healthy Japanese subjects were enrolled. None of them had taken any drug or supplement for at least 1 week before the start of the study.

Study Design {#cpdd259-sec-0040}
------------

This study was a randomized, single‐blind crossover study. In period 1, the subjects received either 300 mg clopidogrel (Sanofi‐Aventis) or 20 mg prasugrel (Daiichi Sankyo) as a single dose during the fasting state in the morning as determined by randomization via computer‐generated random sequences in a 1:1 ratio. The subjects' blood samples were collected for pharmacokinetic and pharmacodynamic analysis. After a more than 2‐week interval (period 2), the drug was switched, and the subjects' blood samples were collected again for pharmacokinetic and pharmacodynamic analysis according to the same collection schedule as used during period 1.

Determination of the Active Drug Metabolites in Plasma {#cpdd259-sec-0050}
------------------------------------------------------

Venous blood samples for determining the plasma concentrations of the active metabolites of prasugrel and clopidogrel were collected in 1/10th volume of 3.2% trisodium citrate before and 0.25, 0.5, 1, 2, and 4 hours after the respective drug administration. The samples were centrifuged at 1710*g* immediately after collection and were stored at --80°C until analysis. The inhibition of platelet aggregation by prasugrel and clopidogrel was measured before and 1, 2, 4, 6, and 8 hours and 10 days after the respective drug administration. The plasma concentrations of the active metabolites were determined using validated liquid chromatography--tandem mass spectrometry methods.[13](#cpdd259-bib-0013){ref-type="ref"}, [14](#cpdd259-bib-0014){ref-type="ref"} The lower limit of detection of both active metabolites is 0.50 ng/mL.

Pharmacokinetic Analysis {#cpdd259-sec-0060}
------------------------

The area under the plasma concentration--time curves (AUC) from 0 to 4 hours and the peak concentration (C~max~) of the active metabolites were derived from the concentration--time data using noncompartmental methods. The AUC values were calculated by the linear trapezoidal method.

Measurement of Platelet Aggregation by Light Transmission Aggregometry {#cpdd259-sec-0070}
----------------------------------------------------------------------

Light transmission aggregometry (LTA) was performed on an MCM hematracer 313‐M (SSR Engineering Co., Ltd., Tokyo, Japan).[15](#cpdd259-bib-0015){ref-type="ref"} Platelet‐rich plasma (PRP) and platelet‐poor plasma (PPP) were prepared from the trisodium citrate--treated venous blood samples by differential centrifugation at room temperature.

PRP and PPP were used for the baseline reading and as a reference corresponding to 100% aggregation, respectively. Aggregation was performed using ADP (20 μM; Chrono‐Log Corp., Havertown, Pennsylvania). The optical density was recorded for 10 minutes at the start of platelet aggregation. The maximal aggregation response (MPA) was recorded and was used for the subsequent analyses. The inhibition of platelet aggregation (IPA) was calculated from the observed MPA at each scheduled point of each treatment using the following formula: IPA (%) = (\[MPA~baseline~ -- MPA~postdose~\]/MPA~baseline~) × 100.

VerifyNow Assay {#cpdd259-sec-0080}
---------------

The VerifyNow system (Accumetrics, San Diego, California) is a turbidimetric‐based optical detection system that measures platelet aggregation as an increase in light transmittance in whole blood. The assay uses reagents based on microbead agglutination technology, in particular, a lyophilized preparation of human fibrinogen‐coated beads, platelet agonists, a preservative, and a buffer solution.[16](#cpdd259-bib-0016){ref-type="ref"}

Citrate‐anticoagulated whole blood was automatically dispensed from the blood collection tube into the assay device by the instrument. ADP was incorporated into the assay channel to induce platelet activation. Light transmittance increased as activated platelets bound and aggregated the fibrinogen‐coated beads. The instrument measured this change in the optical signal, and reported the results in P2Y~12~ (PRU). A higher PRU reflected greater ADP‐mediated platelet reactivity.

Determination of the Vasodilator‐Stimulated Phosphoprotein Phosphorylation Ratio {#cpdd259-sec-0090}
--------------------------------------------------------------------------------

The vasodilator‐stimulated phosphoprotein (VASP) phosphorylation state was determined using an enzyme‐linked immunosorbent assay (CY‐QUANT VASP/P2Y12; France) per the manufacturer\'s instructions.[17](#cpdd259-bib-0017){ref-type="ref"} The platelet reactivity index (PRI) was calculated in the presence of PGE1 alone or PGE1 and ADP.

CYP2C19 Genotyping {#cpdd259-sec-0100}
------------------

Five milliliters of blood was collected from each subject for CYP2C19 genotyping. The crude DNA was extracted from the leukocytes of each subject using a commercially bioavailable kit (Third Wave Technologies, Madison, Wisconsin). The genotyping of the mutated genes CYP2C19 \*2 and \*3 was performed using a polymerase chain reaction--restriction fragment length polymorphism method.[18](#cpdd259-bib-0018){ref-type="ref"}

Data Analysis {#cpdd259-sec-0110}
-------------

The data are presented as the mean ± standard deviation (SD). All data were evaluated using Welch\'s *t* test or a paired *t* test. For the IPA, PRU, and PRI time course determinations, the data were analyzed by repeated‐measures analysis of variance (ANOVA) and the Bonferroni test using SAS software (version 9.2; SAS Institute, Cary, North Carolina). For the AUC, the data were analyzed by ANOVA and Dunnett\'s test, using SPSS software (version 22; Japan IBM, Tokyo, Japan). A *P* ≤ .05 was considered statistically significant.

Results {#cpdd259-sec-0120}
=======

Subjects' Demographics and Adverse Events {#cpdd259-sec-0130}
-----------------------------------------

Thirty‐six of the 40 subjects (14 female and 22 male) completed the study according to the protocol. Two subjects were withdrawn from the study in period 1 because of adverse events (hypotension and pain in fingers), which were, however, not related to prasugrel and clopidogrel. Two subjects withdrew their consent after period 1. Slight prasugrel‐related subcutaneous bleeding occurred in 1 subject; however, the subject completed the study according to the protocol. The CYP2C19 genotyping revealed that there were 8 extensive metabolizers (\*1/\*1), 21 intermediate metabolizers (\*1/\*2 and \*1/\*3), and 7 poor metabolizers (\*2/\*2, \*2/\*3, and \*3/\*3).

Pharmacokinetics of the Active Metabolite of Prasugrel and Clopidogrel {#cpdd259-sec-0140}
----------------------------------------------------------------------

The mean plasma concentration--time curves of the active metabolites of prasugrel and clopidogrel after a single oral dose of 20 mg prasugrel or 300 mg clopidogrel are shown in Figure [1](#cpdd259-fig-0001){ref-type="fig"}a. The plasma concentration of the active metabolite of prasugrel increased rapidly and reached its peak 30 minutes after administration. In contrast, the plasma concentration of the active metabolite of clopidogrel reached its peak 1 hpir after administration. The plasma concentration of prasugrel is shown in Figure [1](#cpdd259-fig-0001){ref-type="fig"}b and that of clopidogrel in Figure [1](#cpdd259-fig-0001){ref-type="fig"}c according to the respective CYP2C19 polymorphism. The mean AUC of the active metabolite of clopidogrel differed significantly between the extensive and intermediate metabolizers, as well as between the extensive and poor metabolizers (Table [1](#cpdd259-tbl-0001){ref-type="table-wrap"}, Figure [1](#cpdd259-fig-0001){ref-type="fig"}c). The C~max~ in the poor metabolizers was significantly lower than that in the extensive metabolizers, but it was quite small (Table [1](#cpdd259-tbl-0001){ref-type="table-wrap"}, Figure [1](#cpdd259-fig-0001){ref-type="fig"}c); however, the mean AUC and C~max~ of the active metabolite of prasugrel were not affected by the CYP2C19 polymorphism (Table [1](#cpdd259-tbl-0001){ref-type="table-wrap"}, Figure [1](#cpdd259-fig-0001){ref-type="fig"}b).

![The plasma concentration of the active metabolites of prasugrel and clopidogrel in 36 subjects after a single oral administration of 20 mg of prasugrel or 300 mg of clopidogrel (a). The plasma concentration of prasugrel (b) and clopidogrel (c) according to the respective CYP2C19 polymorphism. The data represent the mean ± SD; \**P* ≤ .05 versus the poor metabolizers.](CPDD-5-480-g001){#cpdd259-fig-0001}
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Pharmacodynamic Response {#cpdd259-sec-0150}
------------------------

The IPA of prasugrel showed a rapid increase and reached its maximum inhibition 1 hour after administration as measured by LTA, with continued inhibition thereafter. The IPA of clopidogrel, on the other hand, showed a gradual increase and reached its maximum inhibition 2 hours after administration. The IPA of prasugrel was significantly greater than that of clopidogrel (Figure [2](#cpdd259-fig-0002){ref-type="fig"}a). Furthermore, the IPA of clopidogrel in the poor metabolizers was significantly lower (∼30% inhibition) than that in the extensive metabolizers (Figure [2](#cpdd259-fig-0002){ref-type="fig"}b). However, the IPA of prasugrel was not affected by CYP2C19 polymorphisms. The IPA 10 days after prasugrel and clopidogrel administration was 9.0% ± 12.7% and 1.1% ± 20.6%, respectively, at which time the antiplatelet action of both drugs was undetectable. The time to reach 80% of the MPA was 68.2 ± 44.2 and 123.5 ± 56.2 minutes for prasugrel and clopidogrel, respectively.

![The time course of the inhibition of platelet aggregation induced by 20 μM ADP in response to prasugrel or clopidogrel in 36 subjects as determined by the light transmission aggregometry (LTA) assay (a). The inhibition of platelet aggregation by clopidogrel in relation to the respective CYP2C19 polymorphism (b). The data represent the mean ± SD. IPA, inhibition of platelet aggregation. (a) \**P* ≤ .05 versus clopidogrel. (b) \**P* ≤ .05 versus the extensive metabolizers and ^\#^ *P* ≤ .05 versus the intermediate metabolizers.](CPDD-5-480-g002){#cpdd259-fig-0002}

The PRU as determined in the VerifyNow assay and the PRI as determined by the VASP phosphorylation ratio were rapidly reduced by prasugrel, reaching maximum inhibition 1 hour after prasugrel administration. In contrast, the PRU and PRI gradually decreased and reached maximum inhibition 2 hours after the administration of clopidogrel. The PRU and PRI after prasugrel administration were significantly lower than those after clopidogrel administration (Figures [3](#cpdd259-fig-0003){ref-type="fig"}a and [4](#cpdd259-fig-0004){ref-type="fig"}a). The PRU and PRI in the poor metabolizers were significantly higher than those in the extensive metabolizers after clopidogrel administration (Figures [3](#cpdd259-fig-0003){ref-type="fig"}b and [4](#cpdd259-fig-0004){ref-type="fig"}b). The PRU and PRI after prasugrel administration were not affected by CYP2C19 polymorphisms.

![The time course of the P2Y12 reaction unit (PRU) after treatment with prasugrel or clopidogrel in 36 subjects as determined by the VerifyNow assay (a). The PRU after treatment with clopidogrel in relation to the respective CYP2C19 polymorphism (b). The data represent the mean ± SD. PRU, P2Y12 reaction units. (a) \**P* ≤ .05 versus clopidogrel. (b) \**P* ≤ .05 versus the extensive metabolizers.](CPDD-5-480-g003){#cpdd259-fig-0003}

![The time course of the platelet reactivity index (PRI) after treatment with prasugrel or clopidogrel in 36 subjects as determined by the vasodilator‐stimulated phosphoprotein (VASP) phosphorylation ratio (a). The PRI after treatment with clopidogrel in relation to the CYP2C19 polymorphism (b). The data represent the mean ± SD. PRI, platelet reactivity index. (a) \**P* ≤ .05 versus clopidogrel. (b) \**P* ≤ .05 versus the extensive metabolizers and ^\#^ *P* ≤ .05 versus the intermediate metabolizers.](CPDD-5-480-g004){#cpdd259-fig-0004}

The relationship between the antiplatelet effects and the AUC was investigated. A significant (*P* \< .01) correlation was observed between the AUC and the maximum IPA, PRU, and PRI in the clopidogrel group (Figure [5](#cpdd259-fig-0005){ref-type="fig"}). In contrast, prasugrel at a dose of 20 mg had only a submaximal effect with small variations in the IPA, PRU, and PRI, indicating the absence of a correlation between the antiplatelet effects and AUC in the prasugrel group.

![The relationship between the P2Y12 reaction unit (PRU) and area under the curve (AUC) in the clopidogrel treatment group. A significant correlation existed between the PRU and AUC.](CPDD-5-480-g005){#cpdd259-fig-0005}

Discussion {#cpdd259-sec-0160}
==========

In this study a prasugrel loading dose of 20 mg and maintenance dose of 3.75 mg, which was adjusted for Japanese patients with acute coronary syndrome undergoing PCI and for patients undergoing elective PCI, were associated with a low incidence of major adverse cardiovascular events. This was similar to the results of the TRITON‐TIMI 38 study and was indicative of a low risk of clinically serious bleeding.[2](#cpdd259-bib-0002){ref-type="ref"}, [3](#cpdd259-bib-0003){ref-type="ref"} The loading dose of 20 mg prasugrel in Japanese patients is less than that used in Americans and Europeans and is similar to the 3.75‐mg maintenance dose, approved based on phase 1--3 clinical trial data. However, in this study, prasugrel at this relatively low dose of 20 mg showed a platelet aggregation of about 80% in the LTA assay. It was reported that in healthy European subjects, prasugrel at a dose of 60 mg showed about 80% platelet aggregation inhibition, which was almost the same as that in Japanese subjects receiving 20 mg prasugrel.[19](#cpdd259-bib-0019){ref-type="ref"} This might be related to the plasma concentration of the active metabolite of prasugrel in Asian groups being found to be higher than that in white groups.[20](#cpdd259-bib-0020){ref-type="ref"} The lower mean body weight of Asian subjects compared with white subjects may contribute to the higher concentration of the active metabolite in Asians.

In the present study, the concentration of the active metabolite of prasugrel increased rapidly, reaching its peak 30 minutes after administration. The IPA reached its maximum 1 hour after prasugrel administration. In contrast, the IPA of clopidogrel reached its maximum 2 hours after administration. Clopidogrel\'s platelet aggregation inhibition efficacy in the poor metabolizers showed a gradual increase and reached its maximum 4 hours after administration. In Japanese and other Asian subjects, CYP2C19 polymorphisms in poor metabolizers are present in about 20% of the population; therefore, the efficacy of agents affected by CYP2C19 polymorphisms is highly variable, which could explain why there was low responsiveness to clopidogrel in some patients.

The speed of onset of platelet inhibition after receiving antiplatelet agents may be relevant in the setting of acute coronary syndrome or PCI, as rapid onset of antiplatelet activity may inhibit stent thrombosis in PCI. A number of large‐scale pharmacogenomic trials have demonstrated that the response to clopidogrel and interindividual variability in this response were related to CYP2C19 polymorphisms and that poor or nonresponsiveness to clopidogrel was possibly associated with an increased risk of recurrent ischemic events and stent thrombosis in patients receiving drug‐eluting stents.[10](#cpdd259-bib-0010){ref-type="ref"}, [11](#cpdd259-bib-0011){ref-type="ref"}, [12](#cpdd259-bib-0012){ref-type="ref"}, [21](#cpdd259-bib-0021){ref-type="ref"}, [22](#cpdd259-bib-0022){ref-type="ref"} Prasugrel is a more effective inhibitor of platelet aggregation than clopidogrel because of its rapid onset of action with low variability. Therefore, in the TRITON‐TIMI 38 study, prasugrel significantly reduced the incidence of ischemic events (cardiovascular death, fatal myocardial infarction, and nonfatal stroke), urgent target vessel revascularization, and stent thrombosis compared with the results obtained with clopidogrel.[1](#cpdd259-bib-0001){ref-type="ref"} Similar results were found in Japanese patients in the PRASFIT‐ACS[2](#cpdd259-bib-0002){ref-type="ref"} and PRASFIT‐Elective[3](#cpdd259-bib-0003){ref-type="ref"} studies.

Now, clopidogrel as a generic drug can be available, so the cost of clopidogrel is much lower than that of prasugrel. When the drug for treatment is chosen, the cost is one of the major factors.

Conclusions {#cpdd259-sec-0170}
===========

Prasugrel inhibited platelet aggregation more rapidly and more effectively in healthy Japanese subjects than was observed for clopidogrel. The efficacy of prasugrel was not affected by CYP2C19 polymorphisms; therefore, prasugrel\'s inhibition of platelet aggregation showed less variability than that achieved by clopidogrel.
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